Protagonist Therapeutics Inc (PTGX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.76x

Protagonist Therapeutics Inc (PTGX) has a Cash Flow Reinvestment Rate of 0.76x as of March 2025, reinvesting $94.95 Million (capex $545.00K plus investments $-94.40 Million) from operating cash flow of $125.36 Million. Explore Protagonist Therapeutics Inc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.76x
(Capex + Investments) / Operating CF

Total Reinvested

$94.95 Million
Capex + Investments

Operating Cash Flow

$125.36 Million
USD

Capital Expenditures

$545.00K
USD

Protagonist Therapeutics Inc Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Protagonist Therapeutics Inc across 2 annual periods. Also explore Protagonist Therapeutics Inc total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Protagonist Therapeutics Inc (2017–2024)

Year-by-year capital reinvestment analysis for Protagonist Therapeutics Inc. For live market cap and broader valuation context, see PTGX market cap.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.63x $300.84 Million $184.15 Million $1.35 Million ▼ -61.6%
2017 4.26x $16.49 Million $3.87 Million $666.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow